Vaxxinity (VAXX) Competitors

Carisma Therapeutics (NASDAQ:CARM) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.

Does the media prefer CARM or VAXX?

In the previous week, Carisma Therapeutics had 7 more articles in the media than Vaxxinity. MarketBeat recorded 9 mentions for Carisma Therapeutics and 2 mentions for Vaxxinity. Carisma Therapeutics' average media sentiment score of 0.93 beat Vaxxinity's score of 0.57 indicating that Vaxxinity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carisma Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Vaxxinity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CARM or VAXX more profitable?

Vaxxinity has a net margin of 0.00% compared to Vaxxinity's net margin of -582.34%. Vaxxinity's return on equity of -154.04% beat Carisma Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-582.34%	-154.04%	-71.58%
Vaxxinity	N/A	-192.58%	-88.04%

Does the MarketBeat Community prefer CARM or VAXX?

Carisma Therapeutics received 5 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 100.00% of users gave Carisma Therapeutics an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.

Company	Underperform	Outperform
Carisma Therapeutics	Outperform Votes 10 100.00%	Underperform Votes No Votes
Vaxxinity	Outperform Votes 5 38.46%	Underperform Votes 8 61.54%

Which has more risk & volatility, CARM or VAXX?

Carisma Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500.

Do analysts prefer CARM or VAXX?

Carisma Therapeutics presently has a consensus target price of $8.80, suggesting a potential upside of 423.62%. Vaxxinity has a consensus target price of $7.00, suggesting a potential upside of 1,521.50%. Given Carisma Therapeutics' higher probable upside, analysts clearly believe Vaxxinity is more favorable than Carisma Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals believe in CARM or VAXX?

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Vaxxinity shares are held by institutional investors. 17.0% of Carisma Therapeutics shares are held by company insiders. Comparatively, 59.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has higher earnings & valuation, CARM or VAXX?

Vaxxinity has lower revenue, but higher earnings than Carisma Therapeutics. Vaxxinity is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$14.92M	4.66	-$86.88M	-$3.47	-0.48
Vaxxinity	$70K	777.70	-$56.93M	-$0.45	-0.95

Summary

Vaxxinity beats Carisma Therapeutics on 9 of the 17 factors compared between the two stocks.